Qualigen therapeutics, inc. provides corporate update and reports first quarter 2022 financial results

Carlsbad, calif., may 13, 2022 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today announces its financial results for the first quarter ended march 31, 2022, and provides an update on its diagnostics business, therapeutics pipeline, and other corporate developments.
QLGN Ratings Summary
QLGN Quant Ranking